廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8255
    -0.0001 (-0.00%)
     
  • 人民幣

    0.9221
    -0.0007 (-0.08%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.02%)
     
  • 歐元

    8.4406
    +0.0000 (+0.00%)
     
  • 英鎊

    9.8730
    -0.0030 (-0.03%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    69,924.76
    -468.48 (-0.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

  • Merck & Co Inc (NYSE: MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported, citing people familiar with the matter.

  • The Journal mentioned that the deal could be one of the largest takeovers of the year.

  • The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would bolster the pharma giant's cancer-drug portfolio, but no agreement was imminent.

  • Related: SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know.

  • The talks have picked up the pace. The companies are scheduled to meet this week, some people said.

  • WSJ could not tell if Merck had already submitted a formal offer for Seagen.

  • Merck may not be the only suitor, with others also eyeing the cancer-focused biotech, some people told WSJ.

  • The WSJ report notes the tricky nature of the deal, given the heightened risk of a regulatory challenge.

  • Through a 2020 deal, Merck acquired 5 million shares of Seagen for $1 billion. It also paid $600 million upfront for Seagen's LIV-1-targeting antibody-drug conjugates, including the most advanced ladiratuzumab vedotin for breast cancer and other solid tumors.

  • The companies have also teamed up on Seagen's HER2 small molecule drug Tukysa. Merck holds Tukysa rights in Asia, the Middle East, and Latin America.

  • Price Action: SGEN shares are up 3.45% at $180.00, and MRK stock is down 0.25% at $91.77 during the premarket session on the last check Friday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.